United States Precision Medicine Market Report by Product, Technology, Application, End User, States and Company Analysis, 2026-2034

United States Precision Medicine Market Size and Forecast 2026-2034

United States Precision Medicine Market is expected to reach US$ 88.75 Billion by 2034 from US$ 39.54 Billion in 2025, with a CAGR of 9.4% from 2026 to 2034. Rising genomic testing, expanding clinical datasets, targeted therapies, artificial intelligence, personalized oncology, growing biobank investments, advanced sequencing technologies, supportive research infrastructure, and increasing demand for individualized diagnosis and treatment are accelerating precision medicine adoption.

United States Precision Medicine Industry Overview

The United States precision medicine industry is evolving from a research-focused discipline into an increasingly integrated component of modern healthcare. Precision medicine combines genomic, molecular, clinical, environmental, behavioral, and lifestyle information to support more individualized prevention, diagnosis, treatment selection, and disease monitoring. The country benefits from a sophisticated healthcare system, strong biomedical research infrastructure, advanced biotechnology capabilities, extensive electronic health-record networks, and a large ecosystem of pharmaceutical, diagnostic, sequencing, and digital-health companies. Genomic medicine is increasingly used to help diagnose disease, predict outcomes, and guide treatment, particularly where molecular characteristics influence therapeutic decisions. The National Institutes of Health’s All of Us Research Program is further strengthening the research foundation by integrating genomic information with electronic health records, surveys, physical measurements, and wearable-device data.

The scale of available health and genomic information is becoming a major competitive advantage for the United States. In June 2026, NIH reported that more than 747,000 participants had data available to researchers through All of Us, including more than 535,000 whole-genome sequences linked with nearly 482,000 electronic health records. The program’s latest release also introduced proteomics, RNA sequencing, and long-read sequencing datasets, creating broader opportunities for multiomic research. These resources are supporting investigations into disease susceptibility, treatment response, genetic variation, health disparities, and population-level patterns. At the same time, hospitals and academic medical centers are expanding molecular diagnostics, pharmacogenomics, hereditary-disease testing, liquid biopsy, and tumor profiling services.

On the commercial side, precision medicine is closely connected with targeted therapeutics and companion diagnostics. Oncology remains a particularly important application because genetic and molecular biomarkers can identify patients more likely to benefit from specific therapies. FDA activity illustrates this trend: in 2025, more than 90 oncology devices were authorized, including new and expanded companion-diagnostic indications. In 2026, the agency continued expanding companion-diagnostic applications for genomic tests covering biomarkers such as ESR1, HRR genes, PIK3CA, HER2, and RET alterations. Nevertheless, the industry faces challenges involving reimbursement, clinical validation, interoperability, data privacy, unequal access, workforce requirements, and interpretation of complex genomic information. Long-term growth will depend on translating increasingly sophisticated datasets into clinically useful, affordable, equitable, and scalable healthcare solutions.

Recent Developments in United States Precision Medicine Market

• Positive outcomes from Denovo Biopharma's ENLIGHTEN Phase 2b clinical trial for DB104 (liafensine) in the treatment of treatment-resistant depression (TRD) were reported on April 3, 2024. TRD patients who received liafensine had much better outcomes than those who received a placebo, according to the experiment, which was guided by a unique genetic biomarker. A significant advancement in precision medicine for disorders of the central nervous system, the medication showed acceptable tolerance and safety. In addition to working on biomarkers for other significant unmet medical needs, Denovo is currently looking for a worldwide partner to continue developing liafensine. Denovo Biopharma is a clinical-stage biopharmaceutical business with several late-stage medications in development, and liafensine is a first-in-class triple reuptake inhibitor.

Growth Drivers for the United States Precision Medicine Market

Expansion of Genomic and Multiomic Healthcare

The growing availability of genomic and multiomic information is creating a stronger foundation for precision medicine in the United States. Healthcare providers and researchers can increasingly combine DNA sequencing with electronic health records, clinical measurements, wearable information, RNA sequencing, proteomics, and other biological datasets. This integrated approach can reveal relationships between genetic variants, disease development, treatment response, lifestyle, and environmental influences. NIH’s All of Us program illustrates the scale of this transformation. Its June 2026 release included data from more than 747,000 participants, more than 535,000 whole-genome sequences, and additional proteomic, RNA-sequencing, and long-read genomic information. Such datasets provide researchers with greater statistical power and broader population representation. As analytical capabilities improve, healthcare organizations can identify clinically relevant biomarkers, refine disease-risk assessment, and develop more individualized interventions. Consequently, continued expansion of integrated biological and clinical datasets is expected to strengthen precision medicine research, diagnostics, and therapeutic development.

Growth of Targeted and Biomarker-Based Therapies

The increasing development of targeted therapies is directly stimulating demand for precision diagnostics in the United States. Pharmaceutical companies increasingly design treatments around specific molecular alterations, requiring diagnostic tests to determine whether patients possess relevant biomarkers. This creates a closely connected ecosystem involving genomic sequencing, molecular pathology, companion diagnostics, pharmaceutical development, clinical trials, and specialized treatment centers. Oncology provides the clearest example because tumor mutations, gene fusions, protein expression, and other biomarkers can influence therapeutic selection. FDA activity demonstrates continued expansion: the agency authorized more than 90 oncology devices in 2025, including new and expanded companion-diagnostic indications. During 2026, additional approvals expanded genomic testing applications involving PIK3CA, HRR, ESR1, HER2, and RET biomarkers. As targeted medicines become more sophisticated, diagnostic testing becomes increasingly important for identifying appropriate patients, supporting treatment decisions, and monitoring molecular disease characteristics.

Artificial Intelligence and Data-Driven Clinical Decision Making

Artificial intelligence and advanced analytics are becoming important enablers of precision medicine because healthcare organizations generate increasingly large and complex datasets. Genomic sequencing produces extensive molecular information that can be difficult to interpret using conventional analytical approaches. AI and machine-learning technologies can help identify patterns across genomic, clinical, imaging, and longitudinal health datasets, supporting biomarker discovery, patient stratification, risk assessment, and treatment-response analysis. The United States has strong capabilities in both healthcare technology and biomedical research, creating favorable conditions for integration between precision medicine and computational tools. NIH’s All of Us Researcher Workbench provides researchers with secure cloud-based access to integrated health information, including genomic data, electronic health records, surveys, physical measurements, and wearable information. As computational methods become more sophisticated, AI can help convert large-scale datasets into clinically meaningful insights. However, successful implementation requires rigorous validation, explainability, privacy protection, standardized data, and appropriate clinical oversight.

Challenges in the United States Precision Medicine Market

Reimbursement, Cost and Unequal Access

High testing costs, inconsistent reimbursement, and differences in healthcare access remain important barriers to precision medicine adoption. Advanced sequencing, molecular profiling, biomarker testing, and multiomic analysis can require specialized laboratories, expensive instruments, skilled personnel, and sophisticated computational infrastructure. Although precision diagnostics may support more targeted treatment decisions, healthcare providers and payers must evaluate whether testing delivers sufficient clinical and economic value for particular populations. Reimbursement policies can differ according to test type, indication, insurance coverage, and clinical evidence, creating uncertainty for providers and diagnostic developers. Access also varies geographically and across healthcare systems, with major academic centers generally possessing greater genomic capabilities than smaller hospitals and underserved communities. These disparities can limit the equitable distribution of precision medicine benefits. Expanding standardized reimbursement pathways, improving affordability, strengthening laboratory capacity, and increasing patient awareness will be important for broader adoption. Greater integration of precision diagnostics into routine clinical workflows could also help reduce fragmentation and improve access.

Data Privacy, Interpretation and Clinical Integration

The increasing use of genomic and health information creates complex challenges involving privacy, cybersecurity, interpretation, interoperability, and clinical implementation. Precision medicine relies on highly sensitive information that may include genomic sequences, electronic health records, demographic characteristics, insurance information, wearable-device data, and other personal health details. Protecting such information requires robust security systems and strict governance. NIH’s All of Us program, for example, applies dedicated data-security policies and controlled access frameworks to protect participant information while enabling research. Another challenge is interpreting increasingly complex genomic findings. Not every genetic variant has established clinical significance, and translating research findings into actionable medical decisions requires specialized expertise. Healthcare organizations must also integrate molecular test results into electronic health records and existing clinical workflows. Shortages of genetic counselors, molecular pathologists, bioinformatics specialists, and trained clinicians can further restrict implementation. Therefore, standardized data formats, workforce development, secure infrastructure, and evidence-based interpretation frameworks remain essential.

California - Biotechnology, Genomics and Digital Health Convergence

California represents one of the most advanced regional environments for precision medicine in the United States because of its concentration of biotechnology companies, research universities, genomic laboratories, technology firms, hospitals, and venture-backed healthcare innovators. The state benefits from major research centers and a strong life-sciences ecosystem supporting genomic sequencing, molecular diagnostics, bioinformatics, artificial intelligence, cell and gene therapies, and targeted therapeutics. The presence of technology companies further encourages integration between healthcare data, cloud computing, machine learning, and digital health. California is also represented within the broader All of Us ecosystem through genomics partners, including Color in Burlingame, which participates in the program’s genomic infrastructure. Precision medicine activity spans oncology, rare diseases, hereditary conditions, pharmacogenomics, reproductive health, and preventive medicine. The state’s diverse population additionally creates opportunities for research into population-specific genetic variation and health disparities. Continued investment in biotechnology infrastructure, clinical research, sequencing, and computational medicine should maintain California’s position as a leading precision-health innovation center.

Texas - Large-Scale Genomic Research and Clinical Translation

Texas is an important precision medicine market supported by major medical institutions, universities, cancer centers, biotechnology companies, and extensive clinical research capabilities. Houston, Dallas, Austin, and other metropolitan areas provide significant infrastructure for genomics, oncology, molecular diagnostics, and translational medicine. The state’s large and diverse population also creates substantial opportunities for research into genetic variation, disease risk, treatment response, and health disparities. Texas institutions participate in large-scale genomic research initiatives; Baylor College of Medicine, for example, has contributed to the NIH All of Us genomic effort. Oncology remains a particularly strong application area, supported by advanced cancer centers and increasing use of tumor sequencing and biomarker testing. The region is also developing capabilities in artificial intelligence, bioinformatics, cell and gene therapies, and personalized diagnostics. As healthcare providers increasingly integrate genomic information into clinical workflows, Texas can benefit from its combination of research depth, patient volume, specialized medical infrastructure, and biotechnology expertise.

New York - Advanced Medicine and Population-Scale

New York provides a strong environment for precision medicine through its concentration of academic medical centers, pharmaceutical companies, biotechnology firms, diagnostic laboratories, and research institutions. New York City serves as a major hub for clinical research, molecular diagnostics, oncology, genomics, and health technology, while institutions across the state contribute to biomedical innovation. The region’s extensive healthcare infrastructure supports applications including hereditary-disease testing, pharmacogenomics, tumor profiling, rare-disease diagnosis, and individualized treatment selection. New York’s large and diverse population also creates opportunities for research addressing differences in disease prevalence, genetic variation, and treatment outcomes. Hospitals and research organizations increasingly use sequencing and computational tools to improve disease characterization and therapeutic decisions. The state can further benefit from partnerships linking universities, healthcare providers, technology companies, and pharmaceutical developers. As precision medicine moves toward routine clinical use, New York’s combination of population scale, specialist expertise, research infrastructure, and sophisticated healthcare delivery systems provides a strong platform for continued market development.

Florida - Expanding Clinical Adoption and Research Capacity

Florida is developing an increasingly important precision medicine ecosystem supported by large healthcare networks, academic institutions, cancer centers, biotechnology initiatives, and a rapidly growing patient population. The state’s aging population creates substantial demand for advanced approaches to cancer, cardiovascular disease, neurological disorders, and other chronic conditions where individualized diagnosis and treatment can provide clinical value. Major medical institutions are expanding genomic testing, molecular diagnostics, clinical research, and data-driven healthcare capabilities. Florida also contributes to the national precision medicine research ecosystem through organizations involved in the NIH All of Us program. The University of Florida is among institutions participating in the program’s data infrastructure activities. The state’s growing healthcare technology environment creates opportunities for sequencing laboratories, digital health companies, bioinformatics providers, and precision therapeutics developers. Future growth will depend on improving clinical adoption, reimbursement, workforce capabilities, and access to advanced testing beyond major metropolitan centers. These factors can help Florida expand precision medicine across hospitals, specialty clinics, research institutions, and community healthcare settings.

Consumables - Essential Inputs for Precision Testing

Consumables form a foundational component of the precision medicine ecosystem because genomic and molecular testing requires continuous supplies of laboratory materials. The segment includes reagents, assay kits, sequencing chemistry, sample-preparation materials, extraction kits, amplification components, cartridges, microfluidic products, and other single-use laboratory supplies. Demand is closely linked with the volume of sequencing, molecular diagnostics, biomarker testing, liquid biopsy, pharmacogenomic analysis, and research activities. As laboratories adopt higher-throughput sequencing and increasingly complex multiomic workflows, consumables must provide consistent performance, sensitivity, reproducibility, and compatibility with automated systems. The expansion of large genomic databases and research programs also creates recurring requirements for sample processing and sequencing materials. NIH’s All of Us program, for example, continues to generate large volumes of genomic and biological information, supporting ongoing demand for laboratory workflows and related supplies. Future opportunities will increasingly involve specialized consumables for single-cell analysis, long-read sequencing, spatial biology, multiomics, and highly sensitive clinical assays.

Gene Sequencing - The Molecular Data Engine

Gene sequencing represents one of the most important technological foundations of precision medicine because it enables identification and characterization of genetic variations relevant to disease, inherited conditions, treatment response, and cancer biology. Next-generation sequencing supports applications ranging from targeted gene panels and whole-exome sequencing to whole-genome sequencing and tumor profiling. The United States has substantial sequencing infrastructure across academic institutions, commercial laboratories, hospitals, biotechnology companies, and research programs. NIH’s All of Us program reported more than 535,000 whole-genome sequences in its June 2026 data release, demonstrating the growing scale of population-level genomic resources. Sequencing is also becoming increasingly important for companion diagnostics, with FDA authorizations expanding the use of next-generation sequencing tests for biomarker-driven treatments. Technological progress toward longer reads, faster turnaround, improved accuracy, lower costs, and multiomic integration should broaden clinical applications. However, interpretation, reimbursement, laboratory standardization, and data-management requirements remain important considerations.

Oncology - The Leading Precision Treatment Frontier

Oncology represents a major application area for precision medicine because cancer is driven by complex molecular alterations that vary between patients and can change during disease progression. Tumor profiling, liquid biopsy, biomarker testing, companion diagnostics, and genomic sequencing help identify molecular characteristics that may guide targeted treatment decisions. FDA activity continues to demonstrate the expanding relationship between cancer therapeutics and precision diagnostics. In 2025, the FDA reported more than 90 oncology-device authorizations, including new and expanded companion-diagnostic indications. During 2026, the agency expanded diagnostic applications involving biomarkers including PIK3CA, HRR genes, ESR1, HER2, and RET alterations. These developments increase the importance of molecular testing throughout the cancer-care pathway, from diagnosis and treatment selection to monitoring and disease management. Continued development of targeted therapies, immunotherapies, cell therapies, and molecularly defined clinical trials should sustain oncology’s central role in precision medicine. Growth will also depend on affordable testing, rapid turnaround, validated biomarkers, and equitable access to specialized cancer diagnostics.

Hospitals and Clinics - Bringing Personalized Care to Patients

Hospitals and clinics are essential distribution and implementation settings for precision medicine because they connect genomic technologies and molecular diagnostics with actual patient care. Large academic medical centers increasingly integrate sequencing, biomarker testing, pathology, genetic counseling, pharmacogenomics, and multidisciplinary molecular tumor boards into clinical workflows. Hospitals also serve as important sites for precision-medicine clinical trials, particularly in oncology, rare diseases, hereditary disorders, and advanced therapeutics. As testing becomes more accessible, community hospitals and specialty clinics are expected to play a larger role, although differences in infrastructure, workforce, reimbursement, and laboratory capabilities remain barriers. Precision medicine requires coordination between physicians, pathologists, laboratory scientists, genetic counselors, pharmacists, bioinformaticians, and information-technology teams. Electronic health-record integration is particularly important because genomic results must be available when treatment decisions are made. NIH’s All of Us model demonstrates the value of connecting genomic information with longitudinal health records and other data types.

Market Segmentations

Product 

• Consumables
• Instruments
• Services

Technology

• Big Data Analytics
• Bioinformatics
• Gene Sequencing
• Drug Discovery
• Companion Diagnostics
• Others

Application

• Oncology
• Central Nervous System (CNS)
• Immunology
• Respiratory Medicine
• Infections
• Others

End User

• Hospitals and Clinics
• Diagnostic Centers
• Pharma and Biotech Companies
• Healthcare IT Firms
• Others Export

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• AstraZeneca plc
• Bayer AG
• bioMérieux SA
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Illumina Inc.
• Laboratory Corporation of America Holdings
• Merck KGaA
• Novartis AG

Report Details: